Prime Medicine Raises $315M in Funding

14 Jul, 2021

Prime Medicine Raises $315M in Funding
Photo by Paico Oficial on Unsplash

– Prime Medicine is a Cambridge MA-based biotechnology company developing gene editing technology.
– The company raised $115M in Series A funding and $200M in Series B funding.
– The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV, and Newpath Partners.
– The Series B included all Series A investors, plus Casdin Capital with participation from Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group and Samsara BioCapital.

Biotechnology Medical North America
Crunchbase icon

Content report

The following text will be sent to our editors: